Menu

Introducing Vocabria (Cabotegravir) + Rekambys (RILPIVIRINE) 2-monthly long acting injectable treatment


Learn more from a colleague and a patient here
Icon showing a calendar
First and only, complete long-acting injectable regimen for HIV-11,2
Graph icon
The efficacy you have come to expect from daily oral HIV regimens

Monthly Vocabria and Rekambys has non-inferior efficacy to daily oral ARV therapy.1,3–5

2-monthly Vocabria and Rekambys has non-inferior efficacy to monthly Vocabria and Rekambys.1,3–5

Icon showing group of people
Preferred by 98% of patients over daily oral therapy in the ATLAS-2M clinical trial (secondary endpoint)

At Week 48, 98% of 306 patients with no prior exposure to VOCABRIA + REKAMBYS who responded to the questionnaire preferred every 2-month injections vs 1% of 306 patients who preferred the study daily oral lead-in (1% reported no preference).6

Tools and Resources

Tools for your clinic

A range of resources for you and your healthcare team, to help successfully integrate VOCABRIA + REKAMBYS into your clinic.

See resources

Thumbnail of the available HCP resources for the clinic

Getting started with VOCABRIA + REKAMBYS

How long-acting treatment works

Discover how VOCABRIA + REKAMBYS is specifically formulated as a long-acting therapy.

Find out more

Unmet needs in HIV therapy

Learn what patients think about taking daily oral HIV-1 medications

Find out more

Patient
resources

Explore tools and tips to help patients understand what to expect from VOCABRIA + REKAMBYS and their role in treatment success.

Find out more

Need to discuss further?

Icon for CTA Button
Contact us

HIV-1=human immunodeficiency virus type 1; INI=integrase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitors.

References:

  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
  2. REKAMBYS Summary of Product Characteristics. Janssen Healthcare.
  3. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112-1123.
  4. Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020; 382:1124-35. doi: 10.1056/NEJMoa1909512.
  5. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. Published online ahead of print: December 9, 2020. doi: 10.1016/S0140-6736(20)32666-0.
  6. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. Published online ahead of print: December 9, 2020. doi: 10.1016/S0140-6736(20)32666-0. Supplementary material.
  7. de Los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the Positive Perspectives Study. AIDS Behav. Published online ahead of print: October 7, 2020. doi: 10.1007/s10461-020-03055-1.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-210001v3 I April 2022

Prescribing Information

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.